explore -WSS

explore

author：hotspot 2025-10-02 13:14:16 - browse：7897

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： FDA warns J&J's Abiomed: We will regulate your software

leisure time

WSS

Eli Lilly expects to double planned employment in Boston center

Senate committee scrutinizes Medicare Advantage brokers

STAT Summit: How a Chicago ER doctor tackles gun violence

The explosion of genetic testing requires a new approach

Food as medicine: Medically tailored meals may get standardized

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Wikipedia

explore

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

Vertex Pharmaceuticals may move headquarters in Boston

FDA approval of Sarepta Duchenne genetic therapy gives me hope

2023 STAT Wunderkinds: get to know the winners

Affirmative action in medical school literally saved lives

Study says nonprofit hospitals fall short in charity care spending

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CEOs share strategies for surviving biotech slump

State Dept. review finds Biden bears some blame for Afghanistan failures

There's no autism epidemic. It's an autism diagnosis epidemic

hotspot

The Readout: Lenmeldy, GLP

Covid vaccine financial winners and losers, from Pfizer to Novavax

HHS leader on health, climate change and biopharma emissions

Scientists boost immune system in aging mice by making it youthful

There's no autism epidemic. It's an autism diagnosis epidemic

First Opinion Podcast: Long Covid needs a new approach

hotspot

leisure time

explore

entertainment